Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
91 pending office actions • 57 art units • 89 examiners • 0 of 91 (0%) have an AI response strategy ready • 97 patents granted in the last 365 days
University of Pittsburgh has 95 pending office actions in Biotechnology & Pharmaceuticals. Those matters span 92 examiners and 59 art units, creating a wide distribution of prosecution responsibility. The difference between pending matters and examiners indicates that some examiner assignments cover more than one matter, while the art-unit spread is substantially broader than a single-unit portfolio.
FOX, ALLISON M is the busiest examiner with 2 pending matters. That is a limited concentration relative to the portfolio’s overall pending workload, so the data does not identify a dominant examiner relationship. Portfolio management should emphasize centralized tracking, consistent biotechnology claim review, and coordination across the many examiner and art-unit assignments.
The breadth of assignments makes a uniform response strategy less suitable than matter-level review. Examiner history and art-unit practice can be incorporated where relevant, while shared substantive issues can still be coordinated across related applications.
Based on the USPTO statutory response window for each pending office action. 27 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 27 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (2%) |
| §101 + other | 10 (11%) |
| §103 only | 16 (18%) |
| §102 only | 6 (7%) |
| §112 only | 8 (9%) |
| Double-patenting only | 3 (3%) |
| Double-patenting + other | 9 (10%) |
| Multi-statute (no §101) | 35 (38%) |
| No statute on record | 2 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOX, ALLISON M | 2 | 71.0% | +35.7% |
| MACCAGNO, PIERRE L | 2 | 24.3% | +30.8% |
| ROBLES, EILEEN | 1 | 100.0% | +0.0% |
| VIRK, ADIL PARTAP S | 1 | 47.8% | +43.0% |
| ALBERS, KEVIN S | 1 | 25.4% | +50.4% |
| APONTE, MIRAYDA ARLENE | 1 | 63.1% | +21.1% |
| OLAMIT, JUSTIN N | 1 | 62.1% | +9.5% |
| JAFFRI, ZEHRA | 1 | 58.0% | +49.1% |
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
| NEYZARI, OMID | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17047967 | MITOCHONDRIAL RNA IMPORT FOR TREATING MITOCHONDRIAL DISEASE | VYAS, KEYUR ANILKUMAR | 87d overdue |
| 17917873 | Microneedle Array Delivery of Adenovirus Vectored Vaccines With and Without Adjuvants | FREDRICKSON, COURTNEY B | 45d overdue |
| 17930854 | MACHINE LEARNING TECHNIQUES FOR DETECTING REDUCED BLOOD FLOW CONDITIONS | OGLES, MATTHEW ERIC | 10d overdue |
| 17109313 | SUPER ELASTIC, BIOABSORBABLE ENDOVASCULAR DEVICES | BARIA, DINAH N | 8d overdue |
| 17927548 | Adenovirus-Based SARS-CoV-2 Vaccine | ALLEN, MICHAEL D | 3d overdue |
| 18013951 | Electrochemical Biosensors for Rapid and Sensitive Detection of Pathogens and Pathogenic Biomarkers | KAUR, GURPREET | 7d |
| 18992165 | SYSTEMS AND METHODS OF 3D VOLUMETRIC ULTRASOUND IMAGING | VIRK, ADIL PARTAP S | 14d |
| 18879640 | DEVICES, SYSTEMS, AND METHODS FOR PATIENT POSITIONING AND MAINTAINING UPPER AIRWAY PATENCY | ALBERS, KEVIN S | 23d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18992165 | SYSTEMS AND METHODS OF 3D VOLUMETRIC ULTRASOUND IMAGING | VIRK, ADIL PARTAP S | 14d |
| 18879640 | DEVICES, SYSTEMS, AND METHODS FOR PATIENT POSITIONING AND MAINTAINING UPPER AIRWAY PATENCY | ALBERS, KEVIN S | 23d |
| 18878637 | MAXILLO-MANDIBULAR MEASUREMENT TOOL | APONTE, MIRAYDA ARLENE | — |
| 18937726 | DEVICES, SYSTEMS AND METHODS FOR VESSEL LIGATION | JAFFRI, ZEHRA | — |
| 18753253 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF | FOX, ALLISON M | — |
| 18316001 | Artificial Cells and Delivery Devices for Use in Tissue Engineering, and Related Methods | FOX, ALLISON M | — |
| 17716279 | EFFICIENTLY TRAINING AND EVALUATING PATIENT TREATMENT PREDICTION MODELS | MACCAGNO, PIERRE L | — |
| 17760558 | System, Method, and Computer Program Product for Detecting and Responding to Patient Neuromorbidity | MACCAGNO, PIERRE L | — |
| Art Unit | Apps |
|---|---|
| 3771 | 4 |
| 1633 | 4 |
| 1632 | 4 |
| 3791 | 4 |
| 3792 | 3 |
| 1612 | 3 |
| 1634 | 3 |
| 1675 | 3 |
| 1658 | 3 |
| 3772 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19037151 | MODIFICATION OF TISSUE PROPERTIES VIA PHOTOMODULATION | ROBLES, EILEEN | 3792 | §102§103§112 | Non-Final OA | — | Pending | Jan 25, 2025 |
| 18992165 | SYSTEMS AND METHODS OF 3D VOLUMETRIC ULTRASOUND IMAGING | VIRK, ADIL PARTAP S | 3798 | §103§112 | Non-Final OA | 14d | Pending | Jan 07, 2025 |
| 18879640 | DEVICES, SYSTEMS, AND METHODS FOR PATIENT POSITIONING AND MAINTAINING UPPER AIRWAY PATENCY | ALBERS, KEVIN S | 3786 | §103§112 | Final Rejection | 23d | Pending | Dec 27, 2024 |
| 18878637 | MAXILLO-MANDIBULAR MEASUREMENT TOOL | APONTE, MIRAYDA ARLENE | 3772 | §102 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18983967 | SENSORS WITH DEHUMIDIFIERS | OLAMIT, JUSTIN N | 2853 | §102§103§112Other | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18937726 | DEVICES, SYSTEMS AND METHODS FOR VESSEL LIGATION | JAFFRI, ZEHRA | 3771 | §102§103§112 | Final Rejection | — | Pending | Nov 05, 2024 |
| 18925158 | Perfluorocarbon-Containing Contrast Agent for Use in MRI Imaging of Body Cavities | MOSHER, ERIC PARKER | 1612 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18909078 | Powered Wheelchair For Vocational Activities | NEYZARI, OMID | 3613 | §102§103 | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18851534 | ADENO-ASSOCIATED VIRUS VECTORS FOR NUCLEIC ACID DELIVERY TO RETINAL CELLS | SPENCE, JENNIFER SUZANNE | 1633 | §101§102§103§112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18892287 | COMPOSITIONS AND METHODS OF TREATING CORNEAL SCARRING | MI, QIUWEN | — | §102§103 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18847735 | Heparanase Inhibition for Graft Protection | DRISCOLL, LORA E BARNHART | 3991 | §112 | Final Rejection | — | Pending | Sep 17, 2024 |
| 18817667 | CLEAVABLE ACTIVATORS OF CXCR3 AND METHODS OF USE | DHAR, MATASHA | 1632 | §112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18776731 | Decellularization and Functionalization of Extracellular Matrix Biomaterials | FAN, LYNN Y | 1759 | §101§102§112 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18726764 | GLUCAGON PROMOTER FOR DIABETES GENE THERAPY | TIWARI, VYOMA SHUBHAM | 1634 | §102Other | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18758804 | SELECTIVE PEPTIDOMIMETIC MODULATORS OF CAV2.2 (N-TYPE) VOLTAGE-GATED CALCIUM CHANNELS AND USES THEREOF | KOSACK, JOSEPH R | 3991 | §102 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18753253 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF | FOX, ALLISON M | 1633 | §102§103§112DP | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18710080 | POLYMER-BASED GEL IMPLANT FOR RETINAL THERAPY AND METHODS OF MAKING AND USING THE SAME | PACKARD, BENJAMIN J | 1612 | §102§103Other | Non-Final OA | — | Pending | May 14, 2024 |
| 18655945 | ELECTROMAGNETIC SYSTEM FOR RAPID CANNULATION OF FENESTRATED ENDOVASCULAR GRAFTS | RESTAINO, ANDREW PETER | 3771 | §103 | Final Rejection | — | Pending | May 06, 2024 |
| 18655896 | Methods for Preparation of a Terminally Sterilized Hydrogel Derived from Extracellular Matrix | PAGUIO FRISING, MICHELLE F | 1651 | §101DP | Non-Final OA | — | Pending | May 06, 2024 |
| 18706615 | MEDIUM CHAIN DICARBOXYLIC ACIDS FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | KUCKLA, ANNA GRACE | 1626 | §102§112 | Non-Final OA | — | Pending | May 01, 2024 |
| 18703946 | MOLECULES THAT BIND TO CD94/NKG2A HETERODIMER POLYPEPTIDES | HADDAD, MAHER M | 1641 | §102§112 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18700913 | Sacral Neuromodulation for Bowel and Sexual Functions | WEBSTER, KARMEL JOHANNA | 3792 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18699807 | NOVEL TWO ELECTRODE-BASED CORRECTION APPROACH FOR ELIMINATION OF BIOFOULING FROM LABEL-FREE AFFINITY BIOSENSORS FOR DETECTION | SVEIVEN, MICHAEL CAMERON | 1678 | §103§112 | Non-Final OA | — | Pending | Apr 09, 2024 |
| 18698968 | ALDH Inhibitors to Promote Immune Cell Expansion | REDWOOD, CHRISTOPHER EVAN | 1629 | §102§103§112DP | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18624989 | COMBINATION TREATMENT FOR SOLID TUMORS INCLUDING A STING AGONIST AND A CCR2 ANTAGONIST | KIM, DANIELLE A | 1613 | §103 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18694219 | IMPLANTABLE CRANIAL ELECTRONICS | EVANISKO, GEORGE ROBERT | 3792 | §102§103§112 | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18690454 | NON-FUNGIBLE TOKEN SYSTEM FOR ENSURING ETHICAL, EFFICIENT AND EFFECTIVE MANAGEMENT OF BIOSPECIMENS | CELANI, NICHOLAS P | 2449 | §103 | Non-Final OA | 45d overdue | Pending | Mar 08, 2024 |
| 18597764 | CATHETER INSERTION SYSTEMS | ULSH, DUNG T | 3783 | §102§103 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18580805 | MAGNESIUM MESH WITH FEATURES DESIGNED TO BIOABSORB PROGRESSIVELY TO IMPROVE DENTAL BONE REGENERATION | NELSON, MATTHEW M | 3772 | §102 | Final Rejection | 22d | Pending | Jan 19, 2024 |
| 18580741 | MCT11 ANTIBODIES TO TREAT T CELL FUNCTIONAL EXHAUSTION AND ENHANCE CANCER IMMUNOTHERAPY | JUEDES, AMY E | 1644 | §112 | Final Rejection | — | Pending | Jan 19, 2024 |
| 18578660 | DEVICES AND METHODS FOR CONVEYING NEURON SIGNALS TO A PROCESSING DEVICE | ANTISKAY, BRIAN MICHAEL | 3794 | §103 | Final Rejection | 14d | Pending | Jan 11, 2024 |
| 18515076 | DIMERIZATION STRATEGIES AND COMPOUNDS FOR MOLECULAR IMAGING AND/OR RADIOIMMUNOTHERAPY | JONES, DAMERON LEVEST | 1618 | DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18287791 | SMAD2 INHIBITION IN BETA CELLS FOR TYPE 2 DIABETES THERAPY | PRONZATI, GINA | 1633 | §102§103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18480928 | AUGMENTATION OF GAS EXCHANGE BY AN ACOUSTICALLY OSCILLATING MEMBRANE | CHATRATHI, ARJUNA P | 3781 | §103 | Final Rejection | — | Pending | Oct 04, 2023 |
| 18282099 | ALKENE QUINONE COMPOUNDS AND METHODS OF USE | MOU, LIYUAN | 1628 | §103§112 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18461955 | MODIFIED POLYNUCLEOTIDES ENCODING THE SARS-COV-2 SPIKE PROTEIN FOR SAFER DESIGNS OF CORONAVIRUS VACCINES | JADHAO, SAMADHAN JAISING | 1672 | §101§103§112 | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18548875 | SYSTEM AND METHOD FOR ASSESSMENT OF STROKE PATIENTS AND PERSONALIZED REHABILITATION | ABOUELELA, MAY A | 3791 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18454646 | FAT-ASSOCIATED LYMPHOID CLUSTERS AS SITES FOR TRANSPLANTATION, TISSUE REGENERATION, ORGANOGENESIS AND FUNCTION FOR MULTIPLE TISSUES | CONNORS, ALEXANDRA F | 1634 | DP | Final Rejection | — | Pending | Aug 23, 2023 |
| 18277765 | SMALL MOLECULE ALLOSTERIC MODULATORS OF CLASS B GPCR, THE PTHR, AND METHOD TO IDENTIFY THEM | MOORE, SUSANNA | 1624 | §103 | Final Rejection | 36d overdue | Pending | Aug 17, 2023 |
| 18546644 | ENHANCEMENT OF MICROFRACTURE FOR REPAIRING CARTILAGE DEFECTS VIA WNT INHIBITION | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | — | Pending | Aug 16, 2023 |
| 18546032 | HIGH VOLTAGE FLEXIBLE MOLECULAR PIEZOELECTRIC DEVICES | PHAM, EMILY P | 2837 | §102§103 | Non-Final OA | — | Pending | Aug 10, 2023 |
| 18342884 | PEPTIDE ANALOGS CAPABLE OF ENHANCING STIMULATION OF A GLIOMA-SPECIFIC CTL RESPONSE | REDDIG, PETER J | 1646 | Other | Non-Final OA | 5d | Pending | Jun 28, 2023 |
| 18335235 | RNF167 AND CASTOR1 AS NOVEL MTOR TARGETS | GODDARD, LAURA B | 1642 | §112 | Final Rejection | — | Pending | Jun 15, 2023 |
| 18331607 | Targeted Gene Therapies for Pain and Other Neuro-Related Disorders | WEIDNER, ADAM M | 1675 | §112DP | Final Rejection | — | Pending | Jun 08, 2023 |
| 18316001 | Artificial Cells and Delivery Devices for Use in Tissue Engineering, and Related Methods | FOX, ALLISON M | 1633 | §102§103DP | Non-Final OA | — | Pending | May 11, 2023 |
| 18031721 | IMPLANTABLE DEVICES WITH ANTIBACTERIAL COATING | OU, JING RUI | 3771 | §102§103 | Non-Final OA | — | Pending | Apr 13, 2023 |
| 18026041 | BIOCARPET: A LOW PROFILE, MECHANICALLY OPTIMIZED, AND FULLY BIODEGRADABLE ENDOVASCULAR DEVICE FOR TREATMENT OF PERIPHERAL VASCULAR DISEASES | FREAY, CHARLES GRANT | 3746 | §103§112 | Non-Final OA | — | Pending | Mar 13, 2023 |
| 18094535 | ENDOVASCULAR APPARATUS FOR PERFUSING ORGANS IN A BODY | WIEST, PHILIP R | 3781 | §102§103DP | Final Rejection | 7d | Pending | Jan 09, 2023 |
| 18013951 | Electrochemical Biosensors for Rapid and Sensitive Detection of Pathogens and Pathogenic Biomarkers | KAUR, GURPREET | 1759 | §103§112 | Non-Final OA | 7d | Pending | Dec 30, 2022 |
| 17927548 | Adenovirus-Based SARS-CoV-2 Vaccine | ALLEN, MICHAEL D | 1671 | §103§112Other | Final Rejection | 3d overdue | Pending | Nov 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of Pittsburgh has 91 pending office actions as of October 2026, spread across 57 art units and 89 examiners.
Allison M Fox has the most, with 2 of University of Pittsburgh's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
